Brief: BioCorRx Preclinical Data Suggests VDM-001 May Prevent Fentanyl Overdose
03/12/2019 16:09
Dec 3 (Reuters) - BioCorRx Inc BICX.PK :
* BIOCORRX INC - PROVIDED AN UPDATE ON VDM-001, A NEW OPIOID
ANTAGONIST BEING DEVELOPED TO REVERSE OPIOID OVERDOSE
* BIOCORRX INC - EARLY PRECLINICAL DATA SUGGESTS VDM-001 MAY
PREVENT OVERDOSE FROM FENTANYL
* BIOCORRX - EARLY PRECLINICAL DATA SHOWED EFFECTS OF
FENTANYL MAY
BE COMPLETELY PREVENTED BY VDM-001
* BIOCORRX - ONGOING PRECLINICAL WORK IS BEING DIRECTED AT
CONFIRMING BRAIN CONCENTRATIONS OF VDM-001 REQUIRED TO MAXIMIZE
OPIOID ANTAGONIST EFFICACY
* BIOCORRX SAYS "UNLIKE NALOXONE, VDM-001 IS A 100% PURE
SYNTHETIC
ANTAGONIST, WHEREAS NALOXONE RELIES ON NATURAL SOURCES FOR
MANUFACTURING"
* BIOCORRX SAYS NEW PRECLINICAL DATA COUPLED WITH OTHER
CLAIMS
FROM VDM, SUGGEST THERAPEUTIC ADVANTAGES OF VDM-001 OVER
NALOXONE
Source text for Eikon: ID:nGNX4x0x0Z
Further company coverage: BICX.PK
Recent news on Biocorrx
See all newsBrief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104